cannabinoid agonist obesity mechanism

cannabinoid agonist obesity mechanism

Semaglutide May Soon Face Cannabinoid Competition?

Semaglutide may soon face competition from cannabinoid-based therapies, as ART27.13 reduced food-intake bursts by 30% in diet-induced obesity mice in 2024. While GLP-1 agonists have dominated the obesity market, recent pre-clinical data suggest a different pathway can produce similar appetite suppression. Medical Disclaimer: This article is for informational purposes